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A B S T R A C T
Background: Bepridil in combination with aprindine could restore sinus rhythm in patients with
persistent atrial ﬁbrillation (AF). The present study aimed to investigate the electrophysiological
mechanisms of the combined effects of bepridil and aprindine.
Methods: Subjects consisted of 6 dogs without and 6 dogs with atrial rapid pacing (ARP) carried out at
400 bpm for 2 weeks. Bepridil was administered for 1 week in both groups (ARP dogs were administered
bepridil in the second week). The electrophysiological effects of the intravenous administration of
aprindine (1 mg/kg) were evaluated before and after the administration of bepridil.
Results: In non-paced dogs, the atrial effective refractory period (AERP) became longer after the
administration of bepridil (from 151  10 ms to 170  7 ms, p < 0.05); however, no additional AERP
prolongation was observed after the acute administration of aprindine. In ARP dogs, the AERP shortened with
ARP for a week, and tended to lengthen after the administration of bepridil (from 93  5 ms to 118  9 ms,
p = 0.08). In these dogs, the acute aprindine administration did not prolong the AERP before the administration
of bepridil, although it did after the administration of bepridil (from 118  9 ms to 142  8 ms, p < 0.01). AF
duration did not change after the administration of bepridil, although it shortened signiﬁcantly after the
additional administration of aprindine (from 2.2  0.3 s to 1.4  0.8 s, p < 0.05).
Conclusions: Bepridil enhances the effect of aprindine for the prevention of AF by reversing atrial
electrical remodeling.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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The number of patients with atrial ﬁbrillation (AF) is increasing,
and AF is now the most common arrhythmia seen in clinical
practice [1]. Growing evidence has suggested the efﬁcacy of
catheter ablation for AF [2]; however, pharmacotherapy remains
an important treatment option for AF.
If AF is maintained, electrical remodeling develops to increase the
stability [3]. In the process of electrical remodeling, sodium current
(INa) decreases due to the downregulation of the underlying sodium
channel a-subunit expression [4]. Accordingly, sodium channel* Corresponding author at: 2630 Sugitani, Toyama 930-0194, Japan.
Tel.: +81 76 434 7297; fax: +81 76 434 5026.
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0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsblockers are sometimes ineffective in terminating persistent AF. In
this situation, potassium channel blockers are sometimes effective.
Bepridil, a multichannel blocker of rapid, slow, and ultrarapid
delayed rectiﬁer potassium currents (IKr, IKs, and IKur, respectively)
[5,6], sodium current [7], and L- and T-type calcium currents (ICa,L
and ICa,T, respectively) [8,9], is effective in terminating drug-
refractory, persistent AF [10–12]. Moreover, the additional admin-
istration of a sodium channel blocker, aprindine, increases the
success rate of sinus conversion when comparing to patients with
bepridil alone [11,12].
The mechanisms of the combined effects of bepridil and
aprindine remain unclear. In the present study, the combined
effects of bepridil and aprindine on atrial remodeling and AF
development were examined using a canine atrial rapid pacing
(ARP) model with preserved atrioventricular conduction that
develops concomitant tachycardia-induced ventricular dysfunction reserved.
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were observed [14–16].
Methods
Experimental design
The investigation conformed to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH publication No. 85-23, revised 1996). The procedures
were approved by the Animal Research Ethics Committee of the
University of Toyama. Twelve beagles (Sankyo Laboratory, Tokyo,
Japan) of either sex, weighing 9–11 kg, were subjects in the present
study. First, the combined electrophysiological effects of bepridil
and aprindine were determined in 6 non-paced dogs (Fig. 1,
protocol 1). Electrophysiological study (EPS) was performed before
and after the oral administration of bepridil (100 mg/day) for
1 week. Second, the combined effects of bepridil and aprindine
were determined in 6 ARP dogs (Fig. 1, protocol 2). ARP was
performed for 2 weeks, and bepridil was administered for the last
week. EPS was performed at baseline, and after 1 week and 2 weeks
of ARP. In each EPS, electrophysiological properties were deter-
mined before and after the intravenous administration of
aprindine (1 mg/kg).
Animal preparation
ARP dogs were implanted with an atrial pacemaker, as
previously described [14–16]. Dogs were anesthetized with
ketamine (5.0 mg/kg, im), isoﬂurane (induction, 4 vol%; mainte-
nance, 2 vol%), nitrous oxide (1.5 L/min), and oxygen (3.0 L/min),
and ventilated mechanically with a volume-cycled respirator
(607E, Harvard Apparatus, Millis, MA, USA). The left femoral vein
was cannulated to allow infusion of 0.9% saline for replacement of
spontaneous ﬂuid losses. After right lateral thoracotomy at the
fourth intercostal space, a tetrapolar electrode (2 mm inter-
electrode distance, ON202-020, Unique Medical, Osaka, Japan)
was sewn onto the epicardial surface of the right atrium (RA)
for stimulation and recording during serial EPS. The electrode lead
was tunneled subcutaneously to the inter-scapular area andEPS E 
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Fig. 1. Time course of the experiment. Protocol 1. In the experiment with non-paced dogs,
administration of bepridil. Protocol 2. In the experiment with ARP dogs, ARP was performe
EPS was performed each week. The electrophysiological effects of acute intravenous admexteriorized. A screw-in bipolar electrode (CapSureFix 5068,
Medtronic, Minneapolis, MN, USA) was inserted via the right
femoral vein, ﬁxed to the RA appendage, and then connected to an
atrial pacemaker (SIP 501, Star Medical, Tokyo, Japan) in a
subcutaneous pocket created in the abdomen. Atrioventricular
ablation was not performed, and atrioventricular conduction was
preserved. After recovering from anesthesia, the dogs were closely
monitored in an observation room for one day. They were then
moved to a chronic care facility and placed on a 5-day course of
ampicillin sodium and streptomycin sulfate. After a seven-day
period of recovery from pacemaker implantation, the atrial
pacemaker was programmed to pace the atrium at a cycle length
of 150 ms (400 bpm).
Electrophysiological study
Dogs were anesthetized and ventilated in the same manner as
in the initial surgery. In non-paced dogs, stimulation and recording
were performed using electrode catheters inserted into the RA and
the right ventricle via the right jugular vein. In ARP dogs, the atrial
pacemaker was deactivated 30 min before starting each EPS, and
stimulation and recording were performed using the implanted
RA tetrapolar electrode. A cardiac stimulator (SEC-2102, Nihon
Kohden, Tokyo, Japan) was used to deliver square wave pulses of
1 ms in duration. Surface electrocardiogram, RA electrogram, and
right ventricular electrogram were monitored using an oscillo-
scope (VC-11, Nihon Kohden) and recorded on a thermal recorder
(RTA-1200M, Nihon Kohden) at a paper speed of 100 mm/s. These
data were also stored in a digital data recorder (RD-130TE, TEAC,
Tokyo, Japan) for further analyses. P-wave duration, QRS duration,
and QT interval were measured in lead II. The atrial effective
refractory period (AERP) and ventricular effective refractory period
(VERP) (in non-paced dogs only) were measured at the RA and the
right ventricle with a train of 10 basic stimuli (S1) followed by a
premature stimulus (S2) at twice the diastolic threshold. Basic cycle
lengths (BCLs) were 400, 350, 300, 250, and 200 ms for AERP, and
300 and 200 ms for VERP. The coupling interval of S2 was shortened
by a 5 ms step. AERP and VERP were deﬁned as the maximum S1–S2
interval resulting in no atrial and ventricular response, respectively.
AF induction was performed with atrial burst pacing of 20 stimuli atPS 
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 bepridil was orally administered for 1 week. EPS was performed before and after the
d for 2 weeks, and bepridil was started after 1 week of ARP and continued thereafter.
inistration were evaluated. ARP, atrial rapid pacing; EPS, electrophysiological study.
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deﬁned as irregular, repetitive atrial responses lasting more than
1.0 s. AF inducibility was deﬁned as the number of induced AF
episodes out of 10 attempts to induce AF, expressed as a proportion.
AF duration was represented by the mean and the longest duration
of induced AF episodes in each dog. AF cycle length (AFCL) was
measured manually by counting the number of electrograms
present in the trace and then dividing the duration in milliseconds
by the number of electrograms. Inter-atrial conduction time was
deﬁned as the interval between the S1 pacing spike (at a BCL of
200 ms) and the LA electrogram recorded in the trans-esophageal
lead [16]. In non-paced dogs, pharmacological autonomic denerva-
tion was performed with atropine (0.04 mg/kg) and propranolol
(0.2 mg/kg) during the EPS. Pharmacological autonomic denervation
was not performed in ARP dogs because left ventricular dysfunction
was caused in ARP dogs, and pharmacological denervation would
worsen heart failure. Aprindine (1 mg/kg) was intravenously
administered and the measurements were repeated.
Echocardiographic measurements
Transthoracic and transesophageal echocardiography (SSA-
260A, Toshiba, Tokyo, Japan) were performed at the time of every
EPS. All recordings were performed in sinus rhythm with the
pacemaker deactivated. Left ventricular function was determined
by means of transthoracic echocardiography. Left ventricular end-
diastolic (LVDd) and end-systolic dimensions were measured in
the parasternal long-axis view, and left ventricular end-diastolic
and end-systolic volumes were calculated according to the
Teichholz method. The left ventricular ejection fraction (LVEF)
was calculated as the difference between both volumes divided by
the left ventricular end-diastolic volume. LA area was measured in
the two-chamber view by means of transesophageal echocardiog-
raphy.
Statistical analysis
All values are expressed as mean  standard error of the mean
(SEM). An unpaired t-test and a Mann–Whitney U-test were used
to determine the signiﬁcance of differences between the two
groups. The statistical signiﬁcance of multiple-group comparison
was analyzed using one-way analysis of variance (ANOVA), and the
time series data using ANOVA for repeated measures. If one-way
ANOVAs or repeated-measure ANOVAs revealed signiﬁcant effects,
post hoc tests with Bonferroni-adjusted pairwise comparisons
were performed. A p-value <0.05 was considered statistically
signiﬁcant.120
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Fig. 2. Atrial and ventricular effective refractory period in non-paced dogs. AERP at week 0
**p < 0.01 vs. before aprindine. BCL, basic cycle length; ERP, effective refractory periodResults
AERP and VERP in non-paced dogs
At baseline, rate adaption of AERP and VERP was observed
(Fig. 2A and C). The acute intravenous administration of aprindine
prolonged the AERP at each BCL except for 200 ms (Fig. 2A) and the
VERP at 300 ms (Fig. 2C). After administration of bepridil, the AERP
increased from the baseline value (BCL 300 ms, from 151  10 ms
at week 0 to 170  7 ms at week 1, p < 0.05); however, no synergistic
effect of the acute administration of aprindine for AERP prolongation
was observed (Fig. 2B). The VERP did not change after the
administration of bepridil for a week, but the acute administration
of aprindine prolonged the VERP at the BCL of 300 ms (Fig. 2D).
Surface ECG parameters in ARP dogs
Sinus cycle length increased throughout the study protocol
(from 476  24 ms at week 0 to 542  24 ms at week 2, p < 0.05);
however, it did not change after the acute administration of aprindine
at each week (Fig. 3A). P wave duration tended to increase during the
study protocol, but it did not change signiﬁcantly after the acute
administration of aprindine (Fig. 3B). QRS duration became longer
during the study protocol (from 55  2 ms at week 0 to 65  2 ms at
week 2, p < 0.05), and the acute administration of aprindine
lengthened QRS duration at week 0 and week 2 (Fig. 3C). The QT
interval tended to lengthen throughout the protocol, especially after
the administration of bepridil (from 206  5 ms at week 1 to
228  9 ms at week 2, p = 0.09) (Fig. 3D). The acute administration
of aprindine prolonged the QT interval at each week; however, the
increase became smaller after the administration of bepridil. As a
result, QT interval measured after the acute administration of
aprindine did not differ between before and after bepridil adminis-
tration (from 226  7 ms at week 1 to 242  10 ms at week 2,
p = 0.23) (Fig. 3D).
AERP in ARP dogs
The time course of changes in the AERP at the BCL of 250 ms is
shown in Fig. 4A. The AERP shortened after 1 week of ARP, and
recovered after the administration of bepridil during continuous
ARP; however, the degree of this recovery did not reach statistical
signiﬁcance. At baseline, the acute administration of aprindine
signiﬁcantly prolonged the AERP (Fig. 4B); however, the effect of
aprindine disappeared after 1 week of ARP (Fig. 4C). After 1 week of
the administration of bepridil during continuous ARP, aprindine-
induced AERP prolongation was restored (Fig. 4D). As a result, the100
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reached statistical signiﬁcance between week 1 and week 2
(Fig. 4A).
AF Parameters and inter-atrial conduction time in ARP dogs
Changes in AF inducibility were not statistically signiﬁcant
throughout the study because of low AF inducibility (Fig. 5A). AF
duration tended to become longer (from 1.6  0.5 s at week 0 to1
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Fig. 5. AF parameter and inter-atrial conduction time in ARP dogs. Time course of changes
time (D). Panel B. AF duration was not shortened by aprindine at week 1; however, it wa
aprindine. yp < 0.05 and zp < 0.01 vs. week 0, p < 0.01 vs. week 1. ARP, atrial rapid p
conduction time.2.8  0.3 s at week 1, p = 0.66) and was not shortened by aprindine
after 1 week of ARP. AF duration did not change after bepridil
administration during continuous ARP (Fig. 5B); however, it was
signiﬁcantly shortened after the acute administration of aprindine.
AFCL was shortened after 1 week of ARP (from 119  3 ms at week
0 to 99  3 ms at week 1, p < 0.05) and recovered after 1 week of the
administration of bepridil (121  6 ms at week 2, p < 0.01 vs. week 1,
Fig. 5C). The AFCL did not change after the acute administration of
aprindine throughout the study. Inter-atrial conduction time0 1 2
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63  3 ms at week 2, p < 0.01, Fig. 5D). At baseline, the acute
administration of aprindine signiﬁcantly prolonged the inter-atrial
conduction time; however, the effect of aprindine disappeared after
1 week of ARP. After 1 week of administration of bepridil during
continuous ARP, aprindine-induced inter-atrial conduction time
prolongation was restored (Fig. 5D).
Echocardiographic parameters in ARP dogs
The LA area (Fig. 6A) and the LVDd (Fig. 6B) tended to become
larger throughout the study. The LVEF signiﬁcantly decreased after
1 week of ARP, which was not inﬂuenced by 1 week of bepridil
administration during continuous ARP (Fig. 6C).
Discussion
Major ﬁndings
The major ﬁndings of the present study are as follows. First,
bepridil prolonged the AERP in non-paced dogs; however, no
synergistic effect of bepridil and aprindine was observed in these
dogs. Second, bepridil restored AERP shortening caused by ARP and
enhanced AERP prolongation with aprindine. Third, bepridil
enhanced the effect of aprindine on the suppression of AF
perpetuation and the prolongation of inter-atrial conduction time
in ARP dogs.
Potential mechanisms
Rapid atrial excitation during AF causes alteration of atrial
electrophysiological properties, such as shortening of the AERP,
resulting in further promotion of AF [3]. This process is termed
‘‘atrial electrical remodeling.’’ The downregulation of ICaL is the
most important mechanism underlying atrial electrical remodel-
ing [17]. The downregulation of ICaL causes AERP shortening, which
leads to shortening of the AFCL [17].
Bepridil prolongs the action potential duration (APD) via blocking
effects on multiple potassium channels [5,6]. Prolongation of the
APD results in AERP prolongation that inhibits AF perpetuation
[18]. In addition, bepridil reverses atrial electrical remodeling via
inhibition of the transcriptional reduction of the Cav1.2 a-subunit
[18]. Thus, bepridil inhibits AF perpetuation via direct ion channel
blocking effects and reverse remodeling effects. On the other hand,
aprindine exhibits antiarrhythmic effects mainly via the blocking
effect on inactivated sodium channels. Aprindine also has a
potassium channel blocking effect, but this is relatively weak;
accordingly, the APD is shortened by aprindine [19].Sodium channel blockers produce post-repolarization refracto-
riness, a phenomenon of prolongation of the effective refractory
period without prolongation of the APD or greater than prolonga-
tion of the APD [20]. In the present study, the administration of
aprindine prolonged the AERP in non-paced dogs as expected, but
did not prolong it after the administration of bepridil. In this
situation, AERP was sufﬁciently prolonged by bepridil; thus,
additional aprindine might have no margin in prolonging the AERP.
In the present study, the AERP prolongation effect of aprindine
was attenuated after ARP. The APD is considered to be shortened
because of electrical remodeling [14–16]. APD shortening causes a
decrease in inactivated sodium channels [20]; therefore, the effect
of an inactivated sodium channel blocker, aprindine, could be
attenuated. In this situation, bepridil may reinforce the AERP
prolongation effect of aprindine through prolongation of the APD
and an increase in the number of inactivated sodium channels. This
hypothesis is supported by the fact that a similar combined effect
of bepridil and aprindine was observed in inter-atrial conduction
time, which represents the activity of sodium channels.
In contrast to the AERP, the QT interval prolongation effect of
aprindine was decreased after the administration of bepridil. This
suggests that the combined effect of bepridil and aprindine could
be atrial selective. The action potential morphology of atria is
different from that of ventricles [21]. In atria, the resting
membrane potential is more depolarized than in ventricles and
APD displays a more gradual phase 3 repolarization. Therefore,
recovery from the inactivated state of sodium channels is slower in
the atrium. As a result, there is a larger fraction of inactivated
sodium channels in atria than in ventricles. Thus, an inactivated
sodium channel blocker, aprindine, may have an atrial-selective
AERP prolongation effect in the present study.
The combined therapy of bepridil and aprindine suppressed the
AF duration in the present study, possibly through the AERP
prolongation effect of this combined therapy. However, the AFCL
was not prolonged with the additional administration of aprindine.
The combined therapy of bepridil and aprindine could suppress
AF perpetuation through an increase in the excitable gap rather
than prolongation of the AERP. In contrast to the AF duration, the
AF inducibility did not decrease after additional administration
of aprindine. The AF inducibility before acute administration
of aprindine was low throughout the protocol. Thus, additional
aprindine might have no margin in decreasing the AF inducibility.
Potential signiﬁcance
To the best of our knowledge, the present study was the ﬁrst to
demonstrate the mechanisms of the combined effect of bepridil
and aprindine on atrial remodeling and AF. In addition, the present
study suggests the atrial selective effect of the combined therapy of
bepridil and aprindine. The study results provide important
information for clinicians to consider when choosing antiarrhyth-
mic drugs for the treatment of AF.
Possible limitations
The present study was limited in several ways. First, aprindine
was intravenously administered. The acute effect of intravenous
aprindine may differ from the chronic effect of oral aprindine.
Although the onset of action of aprindine is different among routes
of administration, ion channels blocked by aprindine are not
different among them. Furthermore, a previous study [22] reported
that aprindine exhibited consistent anti-arrhythmic effects re-
gardless of routes of administration. However, further studies in
which both bepridil and aprindine are administered orally are
needed to clarify the difference. Second, pharmacological dener-
vation was performed only in non-paced dogs. Accordingly, the
Y. Nakatani et al. / Journal of Cardiology 66 (2015) 445–450450inﬂuence of the autonomic nervous system was not excluded in
ARP dogs. However, this protocol may approximate the clinical
situation. Third, the dose of bepridil (10 mg/kg/day) was higher
than the clinical dose for humans. Thus, our ﬁndings should be
extrapolated to humans cautiously.
Conclusions
Bepridil reversed electrical remodeling of the atrium and
enhanced aprindine-induced AERP prolongation in a canine ARP
model. The combined effects did not appear in the ventricle;
therefore, the effect was considered to be atrial selective.
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